Evaluating new drug candidates for their potential to induce Cytochrome P450 (CYP) enzymes is an important step in the drug discovery and development process. Our CYP induction assays can help to accurately predict the metabolism of drugs in the body.

Our services team offers standardized protocols for two CYP inductions assays, both based on FDA guidance, for assessing gene expression fold-change and enzyme activity of CYP induction.The evaluation focuses on the primary CYPs, such as CYP1A2, CYP2B6, and CYP3A4/5, with further assessment of other CYP2C enzymes recommended if significant induction of CYP3A4/5 occurs.

Accurate in vitro prediction of hepatic clearance (Cl_int) is pivotal for successful drug development. Designing drugs for oral administration with low first-pass metabolism and longer half-lives requires addressing challenges in predicting slow metabolism and low Cl_int values.

TruVivo, an optimized in vitro hepatic system, addresses the shortcomings of standard 2D culture for accurate Cl_int assessment, providing a solution for obtaining more relevant Cl_int data with high IVIVE accuracy.

As Cytochrome P450 (CYP) enzymes are the primary drug metabolizing enzymes in the body, they play a significant role in the metabolic clearance of drugs. CYP inhibition occurs when a new drug inhibits the metabolism of other drugs, increasing drug concentrations in plasma and tissue, reducing drug clearance, and increasing drug toxicity. 



Our services team offers a standardized protocol for assessing direct (IC50), indirect (IC50 Shift Assay), and time-dependent CYP inhibition assays based on FDA guidance, ensuring high-quality data with the speed and accuracy needed for early drug discovery.

Studies conducted to measure metabolic stability of drug products in the liver can be used to inform drug design, predict intrinsic clearance (Cl_int), determine half-life (T_1/2), and support preclinical animal testing and IND submissions.

Learn how our TruVivo 2D+ hepatic system can add important information to understanding the metabolic stability of a compound over extended exposure times in a more in vivo like environment.

In drug discovery, accurately predicting how a drug behaves in the human body is critical. Plasma protein binding (PPB) plays an essential role in regulating drug availabilty, clearance, distribution, and potential interactions.

Our services team offers a standardized protocol for assessing PPB, ensuring high-quality data with the speed and accuracy needed for early drug discovery.

In drug discovery, accurately predicting how a drug behaves in the human body is critical. Microsomal protein binding (MPB) plays an essential role in drug-drug interactions (DDI). Recent guidelines recommend measuring the unbound drug fraction (fu(mic)) to assess DDIs accurately.

Our services team offers a standardized protocol for assessing MPB, ensuring high-quality data with the speed and accuracy needed for early drug discovery.

For new drugs, it is crucial to determine how much of the administered dose will reach systemic circulation and result in the desired efficacious effect, therefore it is essential to develop pharmacokinetic models that accurately predict bioavailability (%F).

Learn how we utilize reliable Caco-2 and EpiIntestinal in vitro models to accurately determine intestinal absorption.

LifeNet Health offers a transporter interactions assay based on the FDA Guidance document entitled, In Vitro Metabolism and Transporter Mediated Drug-Drug Interaction Studies.